Search PubMedSearch

PubMed · 7973205

Estimation and sample size considerations for clustered binary responses.

Abstract

Although there is much literature on sample size determination for clinical trials or experiments with independent responses, there is a lack of methodology to obtain sample sizes for dependent outcomes. This paper presents a simple way to calculate sample size for estimating treatment effects and diagnostic accuracy in the case of correlated binary outcomes. The proposed weighted procedure also has use in estimation, whose advantages we demonstrate through simulation. Recommendations are made for practical application.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E W Lee, N Dubin. 1994-06-30. Estimation and sample size considerations for clustered binary responses.. https://doi.org/10.1002/sim.4780131206

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

New antithrombotic agents.

The development of new antithrombotic agents has been stimulated by clinical needs and by advances in biotechnology that have made it possible to produce drugs that target specific steps in thrombogenesis. Heparin has pharmacokinetic and biophysical limitations that are overcome by new anticoagulants. Of these, low-molecular-weight heparin and direct inhibitors of thrombin have been evaluated clinically. Coumarins require careful laboratory monitoring because of concerns about safety. Orally active direct inhibitors of thrombin and factor Xa may replace coumarins. Aspirin is of limited efficacy because it inhibits only one pathway of platelet activation. Inhibitors of adenosine diphosphate receptor and glycoprotein IIb/IIIa antagonists are more effective than aspirin and are used in the clinic.

Clinical Trials as Topic